Dr Reddy’s Pounces On US Ciprodex Generic As Endo Stumbles
Follows Expiry Of Key Ciprodex Patents
Dr Reddy’s Laboratories has leapfrogged Endo by launching a generic version of of Bayer/Alcon’s Ciprodex (ciprofloxacin/dexamethasone) 0.3%/0.1% otic suspension, as the US firm was stung with a major rejection by the US FDA.
You may also be interested in...
Endo will focus on restructuring initiatives and new launches in 2021 to stabilize its generics business, after the company reported a 20% drop in generics sales for the fourth quarter of 2020, with full-year sales down by more than a tenth.
Hundreds more jobs are to go at Endo under further cost-cutting measures, including the closure of multiple sites serving the US-based player’s Generics business. Management discussed the issue on Endo’s third-quarter earnings call.
Under the terms of a patent-litigation settlement from April 2017, Endo’s Par subsidiary has launched the first US generic versions of BioMarin’s Kuvan (sapropterin) tablet and powder formulations. Rival ANDA sponsor Dr Reddy’s has followed suit on the tablet formulation.